Jeffrey L. Silber

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

21h-index6.2kcitations44works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Herpesvirus Infections and Treatments(16), Clostridium difficile and Clostridium perfringens research(10), Gut microbiota and health(6), Influenza Virus Research Studies(5), Poxvirus research and outbreaks(5)

Publications44 total

A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults
European Journal of Gastroenterology & Hepatology·2025
A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors
ESMO Open·2025· 1 citedOpen Access
Safety and efficacy of a defined bacterial consortium, VE303, to treat HE
Hepatology Communications·2025· 2 citedOpen Access
377. Impact of VE303, a Defined Bacterial Consortium, on Antimicrobial Resistant Gene Prevalence in Patients with <i>Clostridioides difficile</i> Infection (CDI)
Open Forum Infectious Diseases·2025Open Access
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Nature Medicine·2025· 17 cited
607 CONSORTIUM-IO: a phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers
Regular and Young Investigator Award Abstracts·2024· 4 citedOpen Access
43 RECOVERY OF MICROBIOME FUNCTIONAL PATHWAYS INVOLVED IN STICKLAND FERMENTATION IN PATIENTS RECEIVING VE303, A DEFINED BACTERIAL CONSORTIUM FOR CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
Gastroenterology·2024
2140. Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with <i>Clostridioides difficile</i> Infection (CDI): Results from the Phase 2 CONSORTIUM Study
Open Forum Infectious Diseases·2023Open Access
695 PHARMACODYNAMIC RESPONSE TO A DEFINED BACTERIAL CONSORTIUM, VE303, IN PATIENTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION (CDI): RESULTS OF THE PHASE 2 CONSORTIUM STUDY
Gastroenterology·2023· 1 cited
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent <i>Clostridioides difficile</i> Infection
JAMA·2023· 162 citedOpen Access
890: RAPID AND DURABLE COLONIZATION OF VE303 IN CLOSTRIDIODES DIFFICILE INFECTION (CDI) PATIENTS IS ASSOCIATED WITH CLINICAL EFFICACY: RESULTS OF THE PHASE 2 CONSORTIUM STUDY
Gastroenterology·2022· 1 cited
468: DURABLE COLONIZATION OF THE RATIONALLY DESIGNED LIVE BIOTHERAPEUTIC PRODUCTS VE202 AND VE818 IN HEALTHY VOLUNTEERS
Gastroenterology·2022
109: AN 8-STRAIN, RATIONALLY DEFINED BACTERIAL CONSORTIUM, VE303, REDUCES THE RISK OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) RECURRENCE COMPARED WITH PLACEBO IN ADULTS AT HIGH RISK FOR RECURRENCE: RESULTS OF THE PHASE 2 CONSORTIUM STUDY
Gastroenterology·2022· 2 cited
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Cell Host & Microbe·2022· 117 citedOpen Access
Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids
Vaccine·2015· 36 cited
Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster
The Journal of Infectious Diseases·2013· 44 citedOpen Access
Varicella-Zoster Virus-Specific Enzyme-Linked Immunospot Assay Responses and Zoster-Associated Pain in Herpes Zoster Subjects
Clinical and Vaccine Immunology·2012· 9 citedOpen Access
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age
Vaccine·2011· 59 cited
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age
Vaccine·2010· 13 cited
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old
Human Vaccines·2010· 72 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Ivan S. F. Chan(13), Jason M. Norman(12), Rajita Menon(11), Bernat Olle(11), Katia Schlienger(10), Emily Crossette(10), Jeremiah J. Faith(9), Jon E. Stek(9), Myron J. Levin(8), Shakti K. Bhattarai(6), Vanni Bucci(6), F. Schödel(6), Jin Xu(6), Amanda Prince(5), Paul M. Keller(4), Anthony Hayward(4), Christina Y. Chan(4), Paula W. Annunziato(4), Jeffrey G. Smith(4), Michael J. Caulfield(4)